• Je něco špatně v tomto záznamu ?

Ghrelin and endocannabinoids participation in morphine-induced effects in the rat nucleus accumbens

M. Sustkova-Fiserova, P. Jerabek, T. Havlickova, K. Syslova, P. Kacer,

. 2016 ; 233 (3) : 469-484. [pub] 20151028

Jazyk angličtina Země Německo

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc16028038

Grantová podpora
NT13687 MZ0 CEP - Centrální evidence projektů

Digitální knihovna NLK
Plný text - Článek
Zdroj

E-zdroje Online Plný text

NLK ProQuest Central od 1997-02-01 do Před 1 rokem
Medline Complete (EBSCOhost) od 1996-10-01 do Před 1 rokem
Nursing & Allied Health Database (ProQuest) od 1997-02-01 do Před 1 rokem
Health & Medicine (ProQuest) od 1997-02-01 do Před 1 rokem
Psychology Database (ProQuest) od 1997-02-01 do Před 1 rokem

RATIONALE AND OBJECTIVES: In addition to dopamine, endocannabinoids are thought to participate in neural reward mechanisms of opioids. Number of recent studies suggests crucial involvement of ghrelin in some addictive drugs effects. Our previous results showed that ghrelin participates in morphine-induced changes in the mesolimbic dopaminergic system associated with reward processing. The goal of the present study was to test whether the growth hormone secretagogue receptor (GHS-R1A) antagonist JMV2959 was able to influence morphine-induced effects on anandamide (N-arachidonoylethanolamine, AEA) and 2-arachidonoylglycerol (2-AG) in the nucleus accumbens shell (NACSh). METHODS: We used in vivo microdialysis to determine changes in levels of AEA and 2-AG in the NACSh in rats following (i) an acute morphine dose (5, 10 mg/kg s.c.) with and without JMV2959 pretreatment (3, 6 mg/kg i.p.) or (ii) a morphine challenge dose (5 mg/kg s.c.) with and without JMV2959 (3, 6 mg/kg i.p.) pretreatment, administered during abstinence following repeated doses of morphine (5 days, 10-40 mg/kg). Co-administration of ghrelin (40 ug/kg i.p.) was used to verify the ghrelin mechanisms involvement. RESULTS: Pretreatment with JMV2959 significantly and dose-dependently reversed morphine-induced anandamide increases in the NACSh in both the acute and longer-term models, resulting in a significant AEA decrease. JMV2959 significantly intensified acute morphine-induced decreases in accumbens 2-AG levels and attenuated morphine challenge-induced 2-AG decreases. JMV2959 pretreatment significantly reduced concurrent morphine challenge-induced behavioral sensitization. JMV2959 pretreatment effects were abolished by co-administration of ghrelin. CONCLUSIONS: Our results indicate significant involvement of ghrelin signaling in morphine-induced endocannabinoid changes in the NACSh.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc16028038
003      
CZ-PrNML
005      
20170522092131.0
007      
ta
008      
161005s2016 gw f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s00213-015-4119-3 $2 doi
024    7_
$a 10.1007/s00213-015-4119-3 $2 doi
035    __
$a (PubMed)26507196
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gw
100    1_
$a Šustková, Magdaléna $u Department of Pharmacology, Third Faculty of Medicine, Charles University, Ruska 87, Prague 10, 100 34, Czech Republic. magdalena.sustkova@lf3.cuni.cz. $7 xx0074794
245    10
$a Ghrelin and endocannabinoids participation in morphine-induced effects in the rat nucleus accumbens / $c M. Sustkova-Fiserova, P. Jerabek, T. Havlickova, K. Syslova, P. Kacer,
520    9_
$a RATIONALE AND OBJECTIVES: In addition to dopamine, endocannabinoids are thought to participate in neural reward mechanisms of opioids. Number of recent studies suggests crucial involvement of ghrelin in some addictive drugs effects. Our previous results showed that ghrelin participates in morphine-induced changes in the mesolimbic dopaminergic system associated with reward processing. The goal of the present study was to test whether the growth hormone secretagogue receptor (GHS-R1A) antagonist JMV2959 was able to influence morphine-induced effects on anandamide (N-arachidonoylethanolamine, AEA) and 2-arachidonoylglycerol (2-AG) in the nucleus accumbens shell (NACSh). METHODS: We used in vivo microdialysis to determine changes in levels of AEA and 2-AG in the NACSh in rats following (i) an acute morphine dose (5, 10 mg/kg s.c.) with and without JMV2959 pretreatment (3, 6 mg/kg i.p.) or (ii) a morphine challenge dose (5 mg/kg s.c.) with and without JMV2959 (3, 6 mg/kg i.p.) pretreatment, administered during abstinence following repeated doses of morphine (5 days, 10-40 mg/kg). Co-administration of ghrelin (40 ug/kg i.p.) was used to verify the ghrelin mechanisms involvement. RESULTS: Pretreatment with JMV2959 significantly and dose-dependently reversed morphine-induced anandamide increases in the NACSh in both the acute and longer-term models, resulting in a significant AEA decrease. JMV2959 significantly intensified acute morphine-induced decreases in accumbens 2-AG levels and attenuated morphine challenge-induced 2-AG decreases. JMV2959 pretreatment significantly reduced concurrent morphine challenge-induced behavioral sensitization. JMV2959 pretreatment effects were abolished by co-administration of ghrelin. CONCLUSIONS: Our results indicate significant involvement of ghrelin signaling in morphine-induced endocannabinoid changes in the NACSh.
650    _2
$a zvířata $7 D000818
650    _2
$a kyseliny arachidonové $x metabolismus $7 D001095
650    _2
$a vztah mezi dávkou a účinkem léčiva $7 D004305
650    _2
$a endokanabinoidy $x metabolismus $x fyziologie $7 D063388
650    _2
$a extracelulární prostor $x účinky léků $x metabolismus $7 D005110
650    _2
$a ghrelin $x fyziologie $7 D054439
650    _2
$a glyceridy $x metabolismus $7 D005989
650    _2
$a glycin $x analogy a deriváty $x farmakologie $7 D005998
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a morfin $x farmakologie $7 D009020
650    _2
$a narkotika $x farmakologie $7 D009294
650    _2
$a nucleus accumbens $x účinky léků $x metabolismus $7 D009714
650    _2
$a polynenasycené alkamidy $x metabolismus $7 D053284
650    _2
$a krysa rodu Rattus $7 D051381
650    _2
$a potkani Wistar $7 D017208
650    _2
$a receptory ghrelinu $x antagonisté a inhibitory $7 D054440
650    _2
$a receptory somatotropinu $x antagonisté a inhibitory $7 D011986
650    _2
$a stereotypní chování $x účinky léků $7 D013239
650    _2
$a triazoly $x farmakologie $7 D014230
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Jeřábek, Pavel $u Department of Pharmacology, Third Faculty of Medicine, Charles University, Ruska 87, Prague 10, 100 34, Czech Republic. $7 xx0301063
700    1_
$a Havlickova, Tereza $u Department of Pharmacology, Third Faculty of Medicine, Charles University, Ruska 87, Prague 10, 100 34, Czech Republic.
700    1_
$a Syslová, Kamila $u Department of Organic Technology ICT, Laboratory of Medicinal Diagnostics, Technicka 5, Prague 6, 166 28, Czech Republic. $7 xx0145898
700    1_
$a Kačer, Petr, $u Department of Organic Technology ICT, Laboratory of Medicinal Diagnostics, Technicka 5, Prague 6, 166 28, Czech Republic. $d 1969- $7 xx0081992
773    0_
$w MED00003990 $t Psychopharmacology $x 1432-2072 $g Roč. 233, č. 3 (2016), s. 469-484
856    41
$u https://pubmed.ncbi.nlm.nih.gov/26507196 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20161005 $b ABA008
991    __
$a 20170522092525 $b ABA008
999    __
$a ok $b bmc $g 1166352 $s 952668
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 233 $c 3 $d 469-484 $e 20151028 $i 1432-2072 $m Psychopharmacology $n Psychopharmacology $x MED00003990
GRA    __
$a NT13687 $p MZ0
LZP    __
$a Pubmed-20161005

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...